僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Mezagitamab （TAK-079） is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma （RRMM） and idiopathic thrombocytopenic purpura （ITP）